Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...
Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...
Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal ...
COMP360 shows rapid symptom improvement in depression study COMP360 may compete with J&J's Spravato if approved Compass plans FDA meeting for rolling submission Feb 17 (Reuters) - Compass Pathways ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results